3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
Temozolomide
16
Magnetic Resonance Spectroscopy
10
Etoposide
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Bevacizumab
7
Filgrastim
6
Thiotepa
5
Radiation
4
Biopsy
4
Azacitidine
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
sargramostim
3
etoposide phosphate
3
Surveys and Questionnaires
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Methotrexate
3
Irinotecan
3
Gadolinium DTPA
3
Cisplatin
3
Automobiles
3
lutetium Lu 177 dotatate
2
fluorodopa F 18
2
alovudine
2
aldesleukin
2
Yoga
2
Topotecan
2
Thalidomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Ependymoma
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled